Vascularity of tumors has been assessed in studies, in order to correlate the tumor enhancement with gene expression, and it was found that brute enhancement of vascularity is associated with VHL mutation [204], high RUNX3 methylation [224], and good PFS in patients receiving tyrosine kinase inhibitors (TKI) and MRI high vascularity [229]. The gene discussed is RUNX3; the disease is neoplasm.